

Today, the HIV research community is one step closer to finding a cure. In a Canadian first, a…

On July 12th, 2024, the Canadian Institutes for Health Research (CIHR) announced a $25 million investment in the…
PANACHE: Preferences And Needs for Aging Care among HIV-positive Elderly people in Canada
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Determinants of Increased Risk of Cardiovascular Diseases in Individuals Living with HIV
A case-control study of novel bone imaging techniques and plasma markers in HIV-infected persons with or without fragility fractures
Randomized Trial to Prevent Vascular Events in HIV REPRIEVE is the first large-scale randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV.
CTN+ Researchers are the backbone of the Network through generating ideas, collaborating on new initiatives, conducting research, and sharing their knowledge.
Explore Our NetworkInterested in joining the CTN+? We’re always on the lookout for new members to answer the most pressing research questions of today, while anticipating the questions of tomorrow.
Learn More